ZEN-3219

• Description:

  ZEN-3219 is a BET inhibitor with IC50s of 0.48, 0.16 and 0.47 μM for BRD4 (BD1), BRD4 (BD2) and BRD4 (BD1BD2), respectively. ZEN-3219 can be used to form PROTACs to induce degradation of BRD4[1].

• UNSPSC:

  12352005

• Target:

  Epigenetic Reader Domain

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/zen-3219.html

• Purity:

  99.75

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  O=C (C=CC (C1=C (C) ON=C1C) =C2) N2CC3=CC=C (C4OC4) C=C3

• Molecular Formula:

  C19H18N2O3

• Molecular Weight:

  322.36

• References & Citations:

  [1]Kharenko OA, et al. Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine. J Med Chem. 2018 Sep 27;61 (18) :8202-8211.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  BRD4

• CAS Number:

  1952264-34-4